Vasodilator and inotropic therapy for severe chronic heart failure: Passion and skepticism (Q40091787)

17 September 2017

1 reference

title

Vasodilator and inotropic therapy for severe chronic heart failure: passion and skepticism (English)

1 reference

17 September 2017

Vasodilator and inotropic therapy for severe chronic heart failure: Passion and skepticism (English)

1 reference

https://api.crossref.org/works/10.1016/S0735-1097(83)80230-7

12 August 2023

main subject

heart failure

0 references

chronic heart failure

1 reference

Cardiology and cardiovascular medicine

inferred from title

1 reference

https://api.crossref.org/works/10.1016/S0735-1097(83)80230-7

12 August 2023

author name string

M. Packer

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A6138375

12 August 2023

language of work or name

English

0 references

publication date

1 November 1983

1 reference

full work available at URL

17 September 2017

https://api.elsevier.com/content/article/PII:S0735109783802307?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S0735-1097(83)80230-7

https://api.elsevier.com/content/article/PII:S0735109783802307?httpAccept=text/plain

12 August 2023

1 reference

https://api.crossref.org/works/10.1016/S0735-1097(83)80230-7

Journal of the American College of Cardiology

12 August 2023

published in

1 reference

17 September 2017

volume

2

1 reference

17 September 2017

issue

5

1 reference

17 September 2017

page(s)

841-852

1 reference

Oral vasodilator therapy for chronic heart failure: A plea for caution

17 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Physiologic and pharmacologic determinants of vasodilator response: a conceptual framework for rational drug therapy for chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Effects of sublingual administration of nitroglycerin on pulmonary-artery pressure in patients with failure of the left ventricle

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Pharmacological mechanisms for left ventricular unloading in clinical congestive heart failure. Differential effects of nitroprusside, phentolamine, and nitroglycerin on cardiac function and peripheral circulation

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Hemodynamic effects of orally administered isosorbide dinitrate in patients with congestive heart failure.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Hemodynamic and metabolic effects of isosorbide dinitrate in chronic congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Isosorbide dinitrate for the relief of severe heart failure after myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Nitrate effects on cardiac output and left ventricular outflow resistance in chronic congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Determinants of drug response in severe chronic heart failure. 1. Activation of vasoconstrictor forces during vasodilator therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Response of the left ventricle to nitroglycerin in patients with and without mitral regurgitation

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Effect of isosorbide dinitrate on response to submaximal and maximal exercise in patients with congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Improvement in exercise haemodynamics by isosorbide dinitrate in patients with severe congestive cardiac failure secondary to ischaemic heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Nitrate Therapy for Congestive Heart Failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Improved exercise capacity and differing arterial and venous tolerance during chronic isosorbide dinitrate therapy for congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Sustained hemodynamic effects without tolerance during long-term isosorbide dinitrate treatment of chronic left ventricular failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Contrasting immediate and long-term effects of isosorbide dinitrate on exercise capacity in congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Hemodynamic assessment of oral peripheral vasodilator therapy in chronic congestive heart failure: Prolonged effectiveness of isosorbide dinitrate

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Orally administered isosorbide dinitrate in patients with and without left ventricular failure due to acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

New perspectives on therapeutic application of nitrates as vasodilator agents for severe chronic heart failure.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Hemodynamic advantage of combined administration of hydralazine orally and nitrates nonparenterally in the vasodilator therapy of chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Combined oral hydralazine-nitrate therapy in left ventricular failure. Hemodynamic equivalency to sodium nitroprusside

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Oral hydralazine therapy for chronic refractory heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Hemodynamic improvement after oral hydralazine in left ventricular failure: a comparison with nitroprusside infusion in 16 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Beneficial effects of hydralazine in severe mitral regurgitation

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Beneficial effects of hydralazine on rest and exercise hemodynamics in patients with chronic severe aortic insufficiency.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Influence of short-term oral hydralazine therapy on exercise hemodynamics in patients with severe chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Importance of left ventricular chamber size in determining the response to hydralazine in severe chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Acute and long-term effects of vasodilator therapy on resting and exercise hemodynamics and exercise tolerance

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Immediate effects of hydralazine-isosorbide dinitrate combination on exercise capacity and exercise hemodynamics in patients with left ventricular failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Long-term vasodilator therapy for heart failure: clinical response and its relationship to hemodynamic measurements.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Results of long-term vasodilator therapy in patients with refractory congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Hemodynamic evaluation of hydralazine dosage in refractory heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Dose requirements of hydralazine in patients with severe chronic congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Selection of vasodilator drugs for patients with severe chronic heart failure: an approach based on a new classification

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Hemodynamic characterization of tolerance to long-term hydralazine therapy in severe chronic heart failure.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Oral hydralazine in chronic heart failure: sustained beneficial hemodynamic effects

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Hydralazine in the management of left ventricular failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Provocation of myocardial ischemic events during initiation of vasodilator therapy for severe chronic heart failure. Clinical and hemodynamic evaluation of 52 consecutive patients with ischemic cardiomyopathy.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Clinical and experimental studies on the hydralazine syndrome and its relationship to systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Survival in men with severe chronic left ventricular failure due to either coronary heart disease or idiopathic dilated cardiomyopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Hydralazine in the long-term treatment of chronic heart failure: lack of difference from placebo

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Effects of minoxidil on hemodynamics in patients with congestive heart failure.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Sustained effectiveness of minoxidil in heart failure after development of tolerance to other vasodilator drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Sustained reduction of cardiac impedance and preload in congestive heart failure with the antihypertensive vasodilator prazosin

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Differences in hemodynamic effects of nitroprusside and prazosin in severe chronic congestive heart failure: evidence for a direct negative chronotropic effect of prazosin

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Clinical, hemodynamic, and neuroendocrine effects of chronic prazosin therapy for congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Prazosin: the first-dose phenomenon

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Side effects due to treatment of hypertension with prazosin

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Letter: Collapse after prazosin hydrochloride

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Hemodynamic and clinical tachyphylaxis to prazosin-mediated afterload reduction in severe chronic congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Attenuation of Prazosin Effect on Cardiac Output in Chronic Heart Failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Marked early attenuation of hemodynamic effects of oral prazosin therapy in chronic congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Paradox of improved exercise but not resting hemodynamics with short-term prazosin in chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Improved exercise ejection fraction with long-term prazosin therapy in patients with heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Immediate and sustained haemodynamic effects of prazosin during upright exercise in man.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Therapeutic application of prazosin in chronic refractory congestive heart failure. Tolerance and "tachyphylaxis" in perspective

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Increased plasma norepinephrine levels during prazosin therapy for severe congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Increase in plasma norepinephrine during prazosin therapy for chronic congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Prazosin and congestive heart failure: short- and long-term therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Efficacy of prazosin in the management of chronic congestive heart failure: A 6-month randomized, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Effect of prazosin vs placebo on chronic left ventricular heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Long-term therapy of heart failure with prazosin: a randomized double blind trial

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Hemodynamic effects of trimazosin in patients with left ventricular failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Cardiocirculatory effects of afterload reduction with oral trimazosin in severe chronic congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Long-Term Vasodilator Therapy with Trimazosin in Chronic Cardiac Failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Effect of the vasodilator trimazosin versus placebo on exercise performance in chronic left ventricular failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Treatment of Chronic Congestive Heart Failure with Captopril, an Oral Inhibitor of Angiotensin-Converting Enzyme

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Sustained Effectiveness of Converting-Enzyme Inhibition in Patients with Severe Congestive Heart Failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Acute and long-term response to an oral converting-enzyme inhibitor, captopril, in congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Immediate and sustained hemodynamic and clinical improvement in chronic heart failure by an oral angiotensin-converting enzyme inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Angiotensin inhibition in severe heart failure: acute central and limb hemodynamic effects of captopril with observations on sustained oral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Quantitative differences in the hemodynamic effects of captopril and nitroprusside in severe chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Long-term hemodynamic and clinical efficacy of captopril therapy in ambulatory management of severe chronic congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Acute and long-term effects of captopril on exercise cardiac performance and exercise capacity in congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Controlled trial of captopril in chronic heart failure: a rest and exercise hemodynamic study

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

A placebo-controlled trial of captopril in refractory chronic congestive heart failure. Captopril Multicenter Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

A specific orally active inhibitor of angiotensin-converting enzyme in man.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Captopril: an update review of its pharmacological properties and therapeutic efficacy in congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Hemodynamic patterns of response during long-term captopril therapy for severe chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Variable clinical response to long-term angiotensin inhibition in severe heart failure: demonstration of additive benefits of alpha-receptor blockade

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Relation of the renin-angiotensin-aldosterone system to clinical state in congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Captopril-Induced Skin Eruptions

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Development and design of specific inhibitors of angiotensin-converting enzyme

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Captopril: clinical pharmacology and benefit-to-risk ratio in hypertension and congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Evaluation of a long-acting converting enzyme inhibitor (enalapril) for the treatment of chronic congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Clinical use of a calcium antagonistic agent (nifedipine) in acute pulmonary edema

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Hemodynamic effects of nifedipine in congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Haemodynamic effects of nifedipine in heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Hemodynamic and myocardial performance characteristics after verapamil use in congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Regional wall motion from radiopaque markers after intravenous and intracoronary injections of nifedipine

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Impaired early left ventricular relaxation in coronary artery disease: effects of intracornary nifedipine

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Acute hemodynamic responses to sublingual nifedipine: dependence on left ventricular function

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Treatment of hypertension with nifedipine, a calcium antagonistic agent

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Nifedipine, a new antihypertensive with rapid action

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Verapamil therapy for stable and unstable angina pectoris: Calcium channel antagonists in perspective

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Unpredictable response to nifedipine in severe cardiac failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Nifedipine therapy in angina pectoris: evaluation of safety and side effects

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Influence of severity of ventricular dysfunction on hemodynamic responses to intravenously administered verapamil in ischemic heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Prenalterol, a non-selective β-adrenoceptor ligand with absolute β1-selective partial agonist activity

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Hemodynamic actions of prenalterol in severe congestive heart failure due to chronic coronary disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Hemodynamic effects of prenalterol in patients with ischemic heart disease and congestive cardiomyopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Hemodynamic effects of oral pirbuterol in chronic severe congestive heart failure.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Pirbuterol: a new oral sympathomimetic amine for the treatment of congestive heart failure.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Beneficial effect of salbutamol on cardiac function in severe congestive cardiomyopathy. Effect on systolic and diastolic function of the left ventricle

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Hemodynamic assessment of amrinone. A new inotropic agent

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Amrinone: a new non-glycosidic, non-adrenergic cardiotonic agent effective in the treatment of intractable myocardial failure in man

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Sustained hemodynamic and clinical effects of a new cardiotonic agent, WIN 47203, in patients with severe congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

The acute hemodynamic effects of a new agent, MDL 17,043, in the treatment of congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Haemodynamic effects of intravenous amrinone in patients with impaired left ventricular function

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Comparative hemodynamic effects of inotropic and vasodilator drugs in severe heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Hemodynamic effects of pirbuterol in conscious dogs

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Cardiovascular effects of prenalterol on rest and exercise haemodynamics in patients with chronic congestive cardiac failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Pirbuterol, an oral beta-adrenergic receptor agonist, in the treatment of chronic cardiac failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Acute and chronic effects of pirbuterol on left ventricular ejection fraction and clinical status in severe congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Tolerance to dobutamine after a 72 hour continuous infusion

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Hemodynamic comparison of intravenous amrinone and dobutamine in patients with chronic congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Decreased Lymphocyte Beta-Adrenergic-Receptor Density in Patients with Heart Failure and Tolerance to the Beta-Adrenergic Agonist Pirbuterol

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Cardiotonic activity of amrinone--Win 40680 [5-amino-3,4'-bipyridine-6(1H)-one]

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Oral amrinone in refractory congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Amrinone and exercise performance in patients with chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Long-term amrinone therapy in patients with severe heart failure: drug-dependent hemodynamic benefits despite progression of disease

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Side effects of amrinone therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

A new inotropic drug: its promise and a caution

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Biochemical "defect" in the hypertrophied and failing heart: deleterious or compensatory?

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Digitalis-associated cardiac mortality after myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980230-7

7 January 2021

Identifiers

1 reference

17 September 2017

1 reference